Compare Stocks

Date Range: 

 Vasta PlatformPerdoceo EducationBright Scholar EducationArco PlatformiHuman
SymbolNASDAQ:VSTANASDAQ:PRDONYSE:BEDUNASDAQ:ARCENYSE:IH
Price Information
Current Price$9.02$12.01$5.60$27.22$11.41
52 Week RangeBuyBuyN/ABuyBuy
MarketRank™
Overall Score2.02.11.41.81.7
Analysis Score3.53.50.03.53.5
Community Score4.01.52.22.15.0
Dividend Score0.00.02.50.00.0
Ownership Score0.01.70.01.70.0
Earnings & Valuation Score2.53.82.51.90.0
Analyst Ratings
Consensus RecommendationBuyBuyN/ABuyBuy
Consensus Price Target$19.58$20.00N/A$48.50$26.10
% Upside from Price Target117.11% upside66.53% upsideN/A78.18% upside128.75% upside
Trade Information
Market Cap$748.77 million$845.98 million$668.56 million$821.69 million$608.43 million
BetaN/A1.740.970.97N/A
Average Volume105,647457,81735,949244,83297,089
Sales & Book Value
Annual RevenueN/A$627.70 million$491.65 million$139.21 million$30.95 million
Price / SalesN/A1.351.365.9019.66
CashflowN/A$1.48 per share$0.54 per share$0.97 per shareN/A
Price / CashN/A8.1310.4027.98N/A
Book ValueN/A$6.13 per share$3.68 per share$14.68 per shareN/A
Price / BookN/A1.961.521.85
Profitability
Net IncomeN/A$69.98 million$23.51 million$-2,390,000.00$-39,010,000.00
EPSN/A$1.37$0.32$0.49N/A
Trailing P/E Ratio0.006.8629.47160.130.00
Forward P/E Ratio17.357.068.6241.24
P/E Growth0.990.49N/AN/AN/A
Net MarginsN/A18.49%4.62%4.51%N/A
Return on Equity (ROE)N/A23.50%8.63%4.00%N/A
Return on Assets (ROA)N/A17.33%2.72%1.99%N/A
Dividend
Annual PayoutN/AN/A$0.11N/AN/A
Dividend YieldN/AN/A1.96%N/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/A34.38%N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.67%0.14%N/A
Current RatioN/A4.23%1.27%3.02%1.04%
Quick RatioN/A4.23%1.26%2.93%1.00%
Ownership Information
Institutional Ownership PercentageN/A91.90%N/A93.19%N/A
Insider Ownership PercentageN/A3.55%N/AN/AN/A
Miscellaneous
Employees1,9562,55011,4992,746437
Shares Outstanding83.01 million70.44 million119.39 million30.19 million53.32 million
Next Earnings DateN/AN/A7/28/2021 (Estimated)5/26/2021 (Estimated)N/A
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
iHuman Inc. Files 2020 Annual Report on Form 20-FiHuman Inc. Files 2020 Annual Report on Form 20-F
finance.yahoo.com - April 28 at 6:09 PM
Making connections to support disabled young people to live their livesMaking connections to support disabled young people to live their lives
sheffield.ac.uk - April 28 at 8:08 AM
iHuman Inc. (NYSE:IH) Short Interest Up 26.7% in MarchiHuman Inc. (NYSE:IH) Short Interest Up 26.7% in March
americanbankingnews.com - April 19 at 1:20 PM
Study on drugs to prevent skin cancersStudy on drugs to prevent skin cancers
bignewsnetwork.com - April 16 at 8:32 AM
Commonly used drug for neuromuscular diseases could also help prevent certain skin cancersCommonly used drug for neuromuscular diseases could also help prevent certain skin cancers
news-medical.net - April 13 at 9:30 PM
Study suggests common drug could be used to prevent certain skin cancersStudy suggests common drug could be used to prevent certain skin cancers
medicalxpress.com - April 13 at 9:30 PM
Syndicado Snaps Up CPH:DOX Competition Entry ‘Oh, It Hertz!’ (EXCLUSIVE)Syndicado Snaps Up CPH:DOX Competition Entry ‘Oh, It Hertz!’ (EXCLUSIVE)
variety.com - April 13 at 9:30 PM
iHuman Youth Society hosts fundraising event amid increased neediHuman Youth Society hosts fundraising event amid increased need
globalnews.ca - April 2 at 9:47 AM
Youth support in Edmonton crucial, mental-health issues forefront amid COVID-19: iHuman Youth SocietyYouth support in Edmonton crucial, mental-health issues forefront amid COVID-19: iHuman Youth Society
globalnews.ca - April 1 at 1:17 PM
Pfizer Begins Phase I Human Trial Of New Pill To Treat COVID At early Stage Of InfectionPfizer Begins Phase I Human Trial Of New Pill To Treat COVID At 'early Stage Of Infection'
republicworld.com - March 25 at 8:38 AM
iHuman Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial ResultsiHuman Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results
prnewswire.com - March 25 at 2:50 AM
iHuman Inc. to Report Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 25, 2021iHuman Inc. to Report Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 25, 2021
finance.yahoo.com - March 19 at 6:35 AM
Social control in the spotlight with political thriller iHumanSocial control in the spotlight with political thriller 'iHuman'
independent.ie - March 12 at 9:35 PM
The best HR & People Analytics articles of February 2021The best HR & People Analytics articles of February 2021
linkedin.com - March 3 at 11:22 AM
Results of Covaxin study on monkeys outResults of Covaxin study on monkeys out
timesofindia.indiatimes.com - March 3 at 11:22 AM
What Kind Of Shareholders Hold The Majority In iHuman Inc.s (NYSE:IH) Shares?What Kind Of Shareholders Hold The Majority In iHuman Inc.'s (NYSE:IH) Shares?
finance.yahoo.com - March 1 at 8:44 AM
Preserving pulp vitality: part two - vital pulp therapiesPreserving pulp vitality: part two - vital pulp therapies
nature.com - February 12 at 7:58 AM
Vipul Amrutlal Shah Interview with Shilpa Rathnam I Human I Sanak I News18 Star TalkVipul Amrutlal Shah Interview with Shilpa Rathnam I Human I Sanak I News18 Star Talk
msn.com - February 5 at 8:17 PM
Counter vaccine hesitancy by building trustCounter vaccine hesitancy by building trust
tribuneindia.com - January 30 at 7:11 PM
Fringe Q&As: Yianni Agisilaou on his new stand-up show, I, HumanFringe Q&As: Yianni Agisilaou on his new stand-up show, I, Human
heraldscotland.com - January 22 at 7:54 PM
iHuman review: Should we be afraid of a world run by AI?iHuman review: Should we be afraid of a world run by AI?
newscientist.com - January 6 at 7:23 PM
BAT progresses COVID-19 candidate vaccine into Phase I human clinical trialBAT progresses COVID-19 candidate vaccine into Phase I human clinical trial
dailymirror.lk - December 18 at 10:33 PM
First Black commissioner appointed to P.E.I. Human Rights CommissionFirst Black commissioner appointed to P.E.I. Human Rights Commission
msn.com - December 16 at 12:12 AM
Pune-based Gennova to start phase I human trials with 120 volunteers in two hospitalsPune-based Gennova to start phase I human trials with 120 volunteers in two hospitals
financialexpress.com - December 15 at 9:03 AM
P.E.I.s first Black human rights commissioner hoping to make a differenceP.E.I.'s first Black human rights commissioner hoping to make a difference
cbc.ca - December 14 at 6:02 PM
DateCompanyBrokerageAction
5/6/2021Vasta PlatformMorgan StanleyLower Price Target
4/20/2021Vasta PlatformItau BBA SecuritiesInitiated Coverage
12/17/2020Vasta PlatformScotiabankInitiated Coverage
8/25/2020Vasta PlatformUBS GroupInitiated Coverage
8/25/2020Vasta PlatformBank of AmericaInitiated Coverage
8/25/2020Vasta PlatformThe Goldman Sachs GroupInitiated Coverage
9/15/2020Perdoceo EducationBarrington ResearchReiterated Rating
10/22/2019Perdoceo EducationSidotiLower Price Target
8/2/2018Perdoceo EducationPiper Jaffray CompaniesReiterated Rating
7/8/2020Arco PlatformCredit Suisse GroupUpgrade
12/24/2020iHumanNational SecuritiesInitiated Coverage
(Data available from 5/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.